Preview

Научно-практическая ревматология

Расширенный поиск

Фармакогенетика в ревматологии:перспективы индивидуализации фармакотерапии

https://doi.org/10.14412/1995-4484-2005-45

Полный текст:

Список литературы

1. <div><p>Evans W.E., McLeod H.L. Pharmacogenomics — drug disposition, drug targets, and side effects. N. Engl. J. Med., 2003, 34S, 538-549</p><p>Кукес В.Г Клиническая фармакология. М., 2004, 104-167</p><p>Середенин С.Б. Лекции по фармакогенетике. М., МИА, 2004, 303 с</p><p>Баранов B.C., Баранова Е.В., ИващенкоТ.Э., Асеев М.В. Геном человека и гены предрасположенности (Введение в предиктивную медицину). СПб., Интермедика, 2000, 272 с</p><p>Кукес В.Г. Метаболизм лекарственных средств: клинико- фармакологическне аспекты- М., Реафарм, 2004, 18-27, 4047</p><p>Шварц Г.Я. Современные нестероидные противовоспалительные препараты. М., Реафарм., 2004, 81-88</p><p>Vianna-Jorge R., Perini J.A., Rondinclli Е., Suarez-Kurtz G. CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. Clin. Pharmacol. Ther. 2004, 76(1), 18-26</p><p>Garcia-Martin, Martinez, Tabares. et al. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. Clin. Pharmacol. Ther., 2004,76, 119-127</p><p>Lee C.R., Pieper J.A., Frye R.F. et al. Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *l/*2, and *l/*3 genotypes. Eur. J. Clin. Pharmacol., 2003,58,791-794</p><p>Zhang Y„ Zhong D., Si D. Lomoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype. Br. J. Clin. Pharmacol., 2005,59(1), 14-17</p><p>Perini J., Vianna-Jorge R., Suarez-Kurtz G. Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacody­namics of piroxicam in Brazilians. Clin. Pharmacol. Ther.,2005, 77, 403-414</p><p>Yasar U., Eliasson E., Forslund-Bergengren C. et al. The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro. Eur. J. Clin. Pharmacol., 2001,57(10),729-735</p><p>Brenner S.S., HerrlingerC., Dilger K. et al. Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib. Clin. Pharmacokinet.,2003, 42, 283-292</p><p>Kirchheiner J., Stftrmcr E., MeiselC.etal. Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites. Pharmacogenetics, 2003, 13, 473-480</p><p>Tang C., Shou М., Rushmore Т.Н. et al. In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics. Pharmacogenetics, 2001,11, 223-235</p><p>Martinez C., Blanco G., Ladero J.M. et al. Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. Br. J. Pharmacol., 2004, 141,205-208</p><p>Aithal G.P., Day C.P., Leathart J.B., Daly A.K. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac- induced hepatitis. Pharmacogenetics, 2000, 10,511-518</p><p>ScordoM.G., PengoV., Spina E. etal. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin. Pharmacol. Ther., 2002, 72,702710</p><p>Morin S., Bodin L., Loriot M.A. et al. Pharmacogenetics of accnocoumarol pharmacodynamics. Clin. Pharmaco.l Ther., 2004, 75,403-414</p><p>Herman D., Locatelli I., Grabnar I. et al. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. J. Pharmacogenomics. In press 2005.</p><p>Tassies D., Freire C., Pijoan J. et al. Pharmacogenetics of acenocouinarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation. Haematologica, 2002, 87, 1185-1191</p><p>Visser L.E., Schaik R.H., Vliet Mv. M. et al. The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Thromb. Haemost., 2004, 92, 61-66</p><p>Schalekamp Т., van Geest-Daalderop J.H., de Vries- GoldschmedingH.etal. Acenocoumarol stabilization is delayed in CYP2C9*3 carriers. Clin. Pharmacol. Ther., 2004,75,394-402</p><p>Hummers-Pradier E., Hess S., Adham I.M. et al. Determination of bleeding risk using genetic markers in patients taking phenprocoumon. Eur. J. Clin. Pharmacol., 2003,59,213-219</p><p>Higashi M.K., feenstra D.L., Kondo L.M. et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA, 2002, 2871690-1698</p><p>Tabrizi A.R., Zehnbauer B.A., Borecki I.B. et al. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. J. Am. Coll. Surg., 2002,194,267-273</p><p>Hermida J., Zarza J., Alberca I. et al. Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol. Blood, 2002 99, 4237-4239</p><p>Сироткина О.В., Улитина А.С., Тараскина А.Е. с соавт. Аллельные варианты CYP2C9*2 и CYP2C9*3 гена цитохрома CYP2C9 в популяции Санкт-Петербурга и их клиническое значение при антикоагулянтной терапии варфари- ном. Росс, кардиолог, журн., 2004, 6, 24-31</p><p>Peyvandi F., Spreafico М., Siboni S.М. et al. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. Clin. Pharmacol. Ther., 2004, 75(3), 198-203</p><p>JofFe H.V., Xu R., Johnson F.B. et al. Warfarin dosing and cytochrome P450 2C9 polymorphisms. Thromb. Haemost., 2004,91,1123-1128</p><p>You J.H., Chan F.W., Wfang R.S., Cheng G. The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy - a decision analysis. Thromb. Haemost., 2004,92(3),590-597</p><p>DervieuxT., Blanco J.G., Krynetski E.Y. et al. Differing contribution of thiopurinc methyltransferase to mercaptopurine versus thioguaninc effects in human Icukcmic cells. Cancer Res., 2001, 61,5810-5816</p><p>Krynetski E.Y., Evans W.E. Genetic polymorphisms of thiop- urine S-methyltransferase: molecular mechanisms and clinical importance. Pharmacology, 2000,61,136-146</p><p>Yates C.R., Krynetski E.Y., LoennechenT. etal. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann.lntern.Med., 1997, 15,26(8 ), 608-614</p><p>Tai H.L., Krynetski E.Y., Schuetz E.G. et al. Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proc. Natl. Acad. Sci. USA, 1997, 10, 94(12),6444-6449</p><p>Kerstens P.J.S.M., Stolk J.N., DeAbreu R.A. et al. Azathioprine related bone marrow toxicity and low activities of purine enzymes in patients with rheumatoid arthritis. Arthr. Rheum., 1995,38,142-145</p><p>Stolk J.N., Boerbooms A.T., De Abrcu R.A. et al. Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis. Arthr.Rheum., 1998,41, 1858-1866</p><p>Naughton M.A., Battaglia E., O'Brien S. et al. Identification оГ thiopurine methyltransferase polymorph isms cannot predict myelosuppression in sys-temic lupus erythematosus patients taking azathioprine. Rheumatology, 1999, 38,640-644</p><p>Pawlik A, Ostanek L.t Brzosko I. ct al. Increased genotype frequency of N-acetyltransferase 2 slow acctylation in patients with rheumatoid arthritis. Clin. Pharmacol. Ther., 2002, 72(3),319- 325</p><p>Pullar Т. Hunter J.A., Capell H.A. Effect of acetylator phenotype on efficacy and toxicity of sulphasalazine in rheumatoid arthritis. Ann. Rheum. Dis., 1985, 44,831-837</p><p>Bax D.E., Greaves M.S. Amos R.S. Sulphasalazine for rheumatoid arthritis: relationship between dose, acetylator phenotype and response to treatment. Br. J. Rheumatol., 1986,25,282-284</p><p>van Ede A.E., Laan R.F., Blom H.J. ct al. Methotrexate in rheumatoid et al. arthritis: an update with focus on mechanisms involved in toxicity. Semin. Arthr.Rheum., 1998,27,277-292</p><p>Blom H.J., van Riel P.L.C.M., van't Hof M.A. et al. Influence of sulfasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Ann. Rheum. Dis., 1999, 58, 79-84</p><p>Vhn EdeAE., Laan R.F.J.M., Blom H.J. The C677T mutation in the methylenetetrahydrofolate reductase gene-a genetic risk Гас- tor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthr. Rheum., 2001, 44,25252530</p><p>Urano W., Taniguchi A., Yamanaka H. et al. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics, 2002,12,183-190</p></div><br />


Для цитирования:


Sychev D.A., Ignatiev F.V., Kasakov R.E., Ramenskaya G.V., Alexeeva G.N., Zuravleva M.V., Kukes V.G. Фармакогенетика в ревматологии:перспективы индивидуализации фармакотерапии. Научно-практическая ревматология. 2005;43(5):59-63. https://doi.org/10.14412/1995-4484-2005-45

For citation:


Sychev D.A., Ignatiev F.V., Kasakov R.E., Ramenskaya G.V., Alexeeva G.N., Zuravleva M.V., Kukes V.G. Pharmacogenetics in rheumatology: drug therapy individualization perspectives. Rheumatology Science and Practice. 2005;43(5):59-63. (In Russ.) https://doi.org/10.14412/1995-4484-2005-45

Просмотров: 444


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)